| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hemolysis | D006461 | 131 associated lipids |
| Tuberculosis | D014376 | 20 associated lipids |
| Stomach Ulcer | D013276 | 75 associated lipids |
| Nocardia Infections | D009617 | 6 associated lipids |
| Diarrhea | D003967 | 32 associated lipids |
| Hearing Loss, Sensorineural | D006319 | 8 associated lipids |
| Otitis Media | D010033 | 12 associated lipids |
| Carcinoma, Basal Cell | D002280 | 6 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| pmid: | ||||
| Dubé MP et al. | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. | 1999 | Clin. Infect. Dis. | pmid:10028084 |
| Goh KL et al. | Optimal treatment for duodenal ulcer disease: a cost-decision analysis in Malaysian patients. | 1999 | J. Gastroenterol. Hepatol. | pmid:10029275 |
| Horgen L et al. | Postantibiotic effects of rifampin, amikacin, clarithromycin and ethambutol used alone or in various two-, three- and four-drug combinations against Mycobacterium avium. | 1999 | FEMS Immunol. Med. Microbiol. | pmid:10030545 |
| Sakurai K et al. | [Importance of drug selection and the use of sensitivity tests for the eradication therapy for Helicobacter pylori]. | 1999 | Nippon Rinsho | pmid:10036938 |
| Fukazawa K et al. | [Antimicrobial resistance testing of H. pylori epsilometer test and disk diffusion test]. | 1999 | Nippon Rinsho | pmid:10036939 |
| Murakami K and Kimoto M | [Antibiotic-resistant H. pylori strains in the last ten years in Japan]. | 1999 | Nippon Rinsho | pmid:10036940 |
| Maeda S and Yoshida H | [Detection of Helicobacter pylori 23S rRNA gene mutation associated with clarithromycin resistance and its clinical applicability]. | 1999 | Nippon Rinsho | pmid:10036941 |
| Sekine H et al. | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. | 1999 | Nippon Rinsho | pmid:10036947 |
| Iwasaki A | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. | 1999 | Nippon Rinsho | pmid:10036949 |
| Habu Y et al. | [Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease]. | 1999 | Nippon Rinsho | pmid:10036950 |
| Shirai T et al. | [Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer]. | 1999 | Nippon Rinsho | pmid:10036951 |
| Nakagawa M et al. | [A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer]. | 1999 | Nippon Rinsho | pmid:10036952 |
| Kihira K et al. | [Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections]. | 1999 | Nippon Rinsho | pmid:10036953 |
| Goto T et al. | [Erosive duodenitis after eradication therapy for Helicobacter pylori]. | 1999 | Nihon Shokakibyo Gakkai Zasshi | pmid:10047687 |
| Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
| Woo PC et al. | Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model. | 1999 | Pharmacol. Res. | pmid:10051377 |
| Kistler A et al. | Therapeutic dilemma: crescentic mesangiocapillary glomerulonephritis type 1 in a patient on antituberculous therapy with rifampicin. | 1999 | Nephrol. Dial. Transplant. | pmid:10052525 |
| Yan JJ et al. | Disseminated Mycobacterium genavense infection in a patient with acquired immunodeficiency syndrome: first case report in Taiwan. | 1999 | J. Formos. Med. Assoc. | pmid:10063276 |
| Keto Y et al. | Healing of Helicobacter pylori-induced gastric ulcers in Mongolian gerbils: combined treatment with omeprazole and clarithromycin. | 1999 | Dig. Dis. Sci. | pmid:10063909 |
| Nilsson F and Walder M | [Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance]. | 1999 | Lakartidningen | pmid:10064930 |
| Sato K and Tomioka H | [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo]. | 1999 | Kekkaku | pmid:10067057 |
| Schultz-Süchting F et al. | Treatment of Helicobacter heilmannii-associated gastritis in a 14-year-old boy. | 1999 | J. Pediatr. Gastroenterol. Nutr. | pmid:10067743 |
| Vásconez C et al. | Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. | 1999 | J. Hepatol. | pmid:10068106 |
| Dehesa M et al. | [Comparison of 2 schedules based on pantoprazole for eradication of Helicobacter pylori in patients with active duodenal ulcer]. | 1998 Apr-Jun | Rev Gastroenterol Mex | pmid:10068730 |
| Yajima T et al. | Optimum spray congealing conditions for masking the bitter taste of clarithromycin in wax matrix. | 1999 | Chem. Pharm. Bull. | pmid:10071855 |
| Owen RJ | Helicobacter pylori resists arrest. | 1999 | Gut | pmid:10075942 |
| Marais A et al. | Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. | 1999 | Gut | pmid:10075951 |
| Shirtliff ME et al. | Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits. | 1999 | Clin. Orthop. Relat. Res. | pmid:10078148 |
| Periti P and Mazzei T | Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. | 1999 | J Chemother | pmid:10078776 |
| de Jong JJ et al. | Atypical mycobacterium infection with dermatological manifestation in a renal transplant recipient. | 1999 | Transpl. Int. | pmid:10080410 |
| Woo MS et al. | Pediatric transplant grand rounds. A case presentation: skin lesions in a post-lung transplant patient. | 1997 | Pediatr Transplant | pmid:10084776 |
| Moreau P et al. | Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM) | 1999 | Leukemia | pmid:10086745 |
| Unge P | Antibiotic treatment of Helicobacter pylori infection. | 1999 | Curr. Top. Microbiol. Immunol. | pmid:10087665 |
| Wreiber K et al. | [Development of resistant Helicobacter pylori in Sweden. Tendency toward increasing resistance to clarithromycin]. | 1999 | Lakartidningen | pmid:10087796 |
| Sakatani M | [Multi-drug resistant mycobacterial infection]. | 1999 | Ryoikibetsu Shokogun Shirizu | pmid:10088372 |
| GarcÃa-Romero E et al. | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. | 1999 | Gastroenterol Hepatol | pmid:10089703 |
| Ramirez J et al. | Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. | 1999 | Clin Ther | pmid:10090428 |
| Ong EL | Prophylaxis against disseminated Mycobacterium avium complex in AIDS. | 1999 | J. Infect. | pmid:10090497 |
| Sunazuka T et al. | Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. | 1999 | J. Antibiot. | pmid:10092202 |
| Talley NJ et al. | Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. | 1999 | BMJ | pmid:10092259 |
| Khoo KH et al. | Altered expression profile of the surface glycopeptidolipids in drug-resistant clinical isolates of Mycobacterium avium complex. | 1999 | J. Biol. Chem. | pmid:10092667 |
| Torgano G et al. | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. | 1999 | Circulation | pmid:10096930 |
| Navuluri R and Yue S | Understanding peptic ulcer disease pharmacotherapeutics. | 1999 | Nurse Pract | pmid:10100245 |
| Tirén U et al. | Helicobacter pylori gastritis in children: efficacy of 2 weeks of treatment with clarithromycin, amoxicillin and omeprazole. | 1999 | Acta Paediatr. | pmid:10102149 |
| Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
| Zanten SJ et al. | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102960 |
| Van der Wouden EJ et al. | The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102961 |
| Wong BC et al. | Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102962 |
| Xiao SD et al. | High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102963 |
| Liu WZ et al. | Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102964 |
| Huang J and Hunt RH | Clarithromycin-based triple therapies. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102978 |
| Kohyama T et al. | Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. | 1999 | Antimicrob. Agents Chemother. | pmid:10103198 |
| Dempsey CL et al. | Drug usage evaluation: clarithromycin as sequential therapy. | 1993 | Hosp Formul | pmid:10130382 |
| Craig AM et al. | Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. | 1996 | Pharmacoeconomics | pmid:10160472 |
| Gimenez Garcia R et al. | Fish tank granuloma: response to treatment with clarithromycin. | 1999 | J Eur Acad Dermatol Venereol | pmid:10188167 |
| Fournier S et al. | Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10192709 |
| Gómez-Gil E et al. | Clarithromycin-induced acute psychoses in peptic ulcer disease. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10192720 |
| Rosário M et al. | [Profile of the resistance to macrolides and imidazoles of Helicobacter pylori in a sample of the Portuguese population]. | 1998 | Acta Med Port | pmid:10192979 |
| Lee CK et al. | Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. | 1999 | Vaccine | pmid:10195786 |
| Verbanck JJ et al. | Campylobacter jejuni II peritonitis in a CCPD patient: cure by oral clarithromycin. | 1999 Jan-Feb | Perit Dial Int | pmid:10201350 |
| Sonnenberg A et al. | The effect of antibiotic therapy on bleeding from duodenal ulcer. | 1999 | Am. J. Gastroenterol. | pmid:10201462 |
| Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
| Laine L et al. | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. | 1999 | Am. J. Gastroenterol. | pmid:10201465 |
| Zhou Q et al. | CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. | 1999 | Eur. J. Clin. Pharmacol. | pmid:10206083 |
| Miwa H et al. | Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. | 1999 | J. Gastroenterol. Hepatol. | pmid:10207779 |
| Henry DC et al. | Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group. | 1999 | Clin Ther | pmid:10211537 |
| McConnell SA and Amsden GW | Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. | 1999 | Pharmacotherapy | pmid:10212011 |
| Dubois J and St-Pierre C | In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. | 1999 | Diagn. Microbiol. Infect. Dis. | pmid:10212753 |
| Clifford K et al. | Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. | 1999 | Ann. Otol. Rhinol. Laryngol. | pmid:10214783 |
| Kashimura H et al. | Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215732 |
| Lee JM et al. | Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215733 |
| Neville PM et al. | The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215734 |
| Hoffman JS et al. | Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. | 1999 | Aliment. Pharmacol. Ther. | pmid:10215735 |
| Abbott GW et al. | MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. | 1999 | Cell | pmid:10219239 |
| van der Hulst RW et al. | [Treatment of Helicobacter pylori infections]. | 1999 | Ned Tijdschr Geneeskd | pmid:10221109 |
| Khan AA et al. | Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. | 1999 | Int. J. Antimicrob. Agents | pmid:10221415 |
| Sato K and Tomioka H | Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. | 1999 | J. Antimicrob. Chemother. | pmid:10223590 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Fish DN and Abraham E | Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. | 1999 | Antimicrob. Agents Chemother. | pmid:10223952 |
| Bergman KL et al. | Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. | 1999 | Antimicrob. Agents Chemother. | pmid:10223956 |
| Gisbert JP et al. | [Antral biopsy is sufficient to confirm Helicobacter pylori eradication with the "new" one-week long triple treatments]. | 1999 | Med Clin (Barc) | pmid:10227015 |
| Gisbert JP | [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. | 1999 | Rev Esp Enferm Dig | pmid:10231305 |
| Goddard AF et al. | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233187 |
| Pilotto A et al. | The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233191 |
| Hayashi Y et al. | Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. | 1999 | Pacing Clin Electrophysiol | pmid:10234723 |
| Vakil N and Cutler A | Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10235192 |
| Woods GL et al. | Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. | 1999 | J. Clin. Microbiol. | pmid:10325306 |
| Warheker PT et al. | Successful treatment of saccular endophthalmitis with clarithromycin. | 1998 | Eye (Lond) | pmid:10326009 |
| Carbon C and Poole MD | The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. | 1999 | J Chemother | pmid:10326741 |
| Le Gars L et al. | Polyarthralgia-arthritis syndrome induced by low doses of rifabutin. | 1999 | J. Rheumatol. | pmid:10332992 |
| Bocheńska-Marciniak M et al. | [Clinical efficacy and safety of spiramycin and clarithromycin in the treatment of outpatients with lower respiratory tract infections]. | 1998 | Pol. Arch. Med. Wewn. | pmid:10335027 |
| Champney WS and Tober CL | Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. | 1999 | Curr. Microbiol. | pmid:10341075 |
| Nitu IC et al. | Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. | 1999 | Clin Lab Haematol | pmid:10342075 |
| Abdul Aal GM et al. | Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week. | 1999 | Digestion | pmid:10343145 |
| Dajani AI et al. | One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases. | 1999 | Digestion | pmid:10343146 |
| Sonnenberg A et al. | Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. | 1999 | Am J Manag Care | pmid:10345967 |
| Champney WS and Tober CL | Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. | 1999 | Antimicrob. Agents Chemother. | pmid:10348746 |
| Debets-Ossenkopp YJ et al. | Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. | 1999 | J. Antimicrob. Chemother. | pmid:10350380 |
| Son SW et al. | The response of rosacea to eradication of Helicobacter pylori. | 1999 | Br. J. Dermatol. | pmid:10354058 |